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Background: The Human Immunodeficiency Virus type-1 (HIV-1) spreads by cell-free diffusion and by direct cell-to-cell
transfer, the latter being a significantly more efficient mode of transmission. Recently it has been suggested that
cell-to-cell spread may permit ongoing virus replication in the presence of antiretroviral therapy (ART) based on studies
performed using Reverse Transcriptase Inhibitors (RTIs). Protease Inhibitors (PIs) constitute an important component of
ART; however whether this class of inhibitors can suppress cell-to-cell transfer of HIV-1 is unexplored. Here we have
evaluated the inhibitory effect of PIs during cell-to-cell spread of HIV-1 between T lymphocytes.
Results: Using quantitative assays in cell line and primary cell systems that directly measure the early steps of HIV-1
infection we find that the PIs Lopinavir and Darunavir are equally potent against both cell-free and cell-to-cell spread of
HIV-1. We further show that a protease resistant mutant maintains its resistant phenotype during cell-to-cell spread and
is transmitted more efficiently than wild-type virus in the presence of drug. By contrast we find that T cell-T cell spread
of HIV-1 is 4–20 fold more resistant to inhibition by the RTIs Nevirapine, Zidovudine and Tenofovir. Notably, varying the
ratio of infected and uninfected cells in co-culture impacted on the degree of inhibition, indicating that the relative
efficacy of ART is dependent on the multiplicity of infection.
Conclusions: We conclude that if the variable effects of antiviral drugs on cell-to-cell virus dissemination of HIV-1 do
indeed impact on viral replication and maintenance of viral reservoirs this is likely to be influenced by the antiviral drug
class, since PIs appear particularly effective against both modes of HIV-1 spread.
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Combination antiretroviral therapy (cART) for the treat-
ment of Human Immunodeficiency Virus Type-1 (HIV-1)
infection is very effective and has transformed Acquired
Immunodeficiency Syndrome (AIDS) from a fatal disease
into a manageable chronic condition. Despite the success
of existing therapies in controlling viral replication and
preventing disease progression, treatment is not curative
and remains a life-long commitment for infected patients.
The ability of the virus to persist in reservoirs within the
body, re-emerge in the face of therapeutic lapses and to
evolve drug resistant variants continues to frustrate the ef-
forts towards finding a definitive cure. A good under-
standing of the mechanisms of viral persistence in the* Correspondence: c.jolly@ucl.ac.uk
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stated.context of antiretroviral therapy is crucial for developing
novel eradication strategies.
Cellular reservoirs are recognized key drivers of viral
persistence within the host [1]. Ongoing viral replication
in patients receiving cART is debated as a mechanism
for viral persistence with opposing lines of evidence both
in support of [2-4] and against [5-7] this mechanism of
persistence. In support of full suppression of viral replica-
tion with cART, patients with good adherence to treatment
do not show evidence of viral evolution and treatment fail-
ure; also no further decrease of residual viremia is seen
with intensification of cART regimens [5-7]. However, re-
cent treatment intensification studies with the Integrase
Inhibitor (INI) Raltegravir have noted an increase in epi-
somal DNA and a reduction in the size of the latent reser-
voir [2-4]. These studies suggest that there is ongoing
residual viral replication, which may be suppressed by ad-
dition of INIs to existing treatment regimens.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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either by cell-free infection or by cell-to-cell spread at
virological synapses (VS). Cell-to-cell spread is a very ef-
ficient mode of retroviral dissemination, which allows
for directed virus transfer across a virological synapse,
obviating the need for prolonged cell-free virus diffusion
[8-10]. Notably, this mode of virus spread is several orders
of magnitude more efficient than classical cell-free diffusion
[11-13] and may be more resistant to neutralization by anti-
bodies [10,14-17]. Furthermore, it has been proposed that
the replicative advantages conferred by cell-to-cell spread,
mediated during physical contact between infected and un-
infected cells, may be important in lymphoid tissues where
CD4+ T lymphocytes are densely-packed and likely to fre-
quently interact. Indeed, studies using intravital imaging
have validated the concept of the VS in vivo [18,19]. More
recently it has been suggested that cell-to-cell virus transfer
may be a mechanism by which HIV-1 can evade ART, and
thus continue to replicate at low levels in the presence of
ongoing therapy [20]. In that study, Sigal et al. proposed
that the large number of viral particles which are transmit-
ted to an uninfected target cell during cell-to-cell transfer
increases the probability that at least one viral particle will
stochastically escape inhibition by drugs and proceed to in-
fect the cell [20]. They tested this hypothesis by assessing
the effects of RTIs on virus spread in an in vitro experimen-
tal model and showed that cell-to-cell spread was less sensi-
tive to inhibition by RTIs than cell-free transmission [20]. A
similar mechanism of saturation of inhibitors by a large
pool of incoming virus particles has also been suggested to
explain the resistance of cell-to-cell virus transfer to inhib-
ition by innate, antiviral cellular factors [21,22]. However, in
a conflicting report Permanyer et al. conducted similar
in vitro assays and reported that RTIs were equally effective
at blocking both modes of HIV-1 dissemination [23]. The
disparity in these studies therefore raises questions regard-
ing the true impact of antiretrovirals on cell-to-cell HIV-1
transmission. Moreover, because both studies restricted
their analysis to RTIs it remains unclear whether the differ-
ent drug classes that constitute cART vary in their ability to
block cell-to-cell spread of HIV-1.
Protease Inhibitors constitute an important compo-
nent of cART by virtue of their potency and the high
barrier that they impose against selection of drug resistant
variants [24,25]. PIs are the only class of antiretroviral
drugs, which have been tested for use as monotherapy for
the treatment of HIV and shown to be not inferior to
cART regimens in maintaining suppression of viral repli-
cation [26,27]. While PIs are mostly reserved for use in
2nd line therapy in developing countries when 1st line
therapies fail, the rise in circulating baseline resistance to
RTIs in treatment naïve individuals [28,29] has led to in-
creased use of PI-based cART for first-line treatment, mak-
ing this drug class particularly important for the future ofHAART. PIs are known to act by preventing cleavage of
viral polyproteins into functional subunits, thereby inhibit-
ing maturation of the virus. A recent study has suggested
that in mediating their antiviral effects, PIs affect multiple
distinct steps in the life-cycle of the virus including both
entry and post-entry events explaining their remarkable
potency in suppressing viral replication [30]. During cell-
to-cell spread, virus assembly and budding are polarized
towards the cell-cell interface [9,10]. Therefore it is pos-
sible that de novo viral HIV-1 assembly and maturation at
the VS, coupled with more rapid virus transfer, might limit
the efficacy of PIs during cell-to-cell spread. However the
impact of PIs on cell-to-cell transfer of HIV-1 has not been
investigated.
Here we have specifically compared the relative efficacy
of PIs during cell-free and cell-to-cell spread of HIV-1 be-
tween T lymphocytes. We find that PIs (Lopinavir and
Darunavir) are equally effective at blocking both modes of
HIV-1 spread at similar IC50 concentrations. We also
show that a mutant of HIV-1 containing well-defined
Lopinavir resistance mutations retains its resistance profile
during cell-cell spread. By contrast we observe that cell-
to-cell spread of HIV-1 is less inhibited by RTIs but note
intra-class differences in the ability of RTIs to block cell-
to-cell spread, with some NRTIs being far less effective
than NNRTIs. Taken together these data reveal that while
PIs are potent inhibitors of cell-to-cell spread, different
classes of antiretroviral drugs display variable efficacy
against different modes of HIV-1 dissemination. Thus if
cell-to-cell spread of HIV-1 does indeed impact ongoing
viral replication and maintenance of reservoirs in treated
patients, it does so in a drug-class dependent manner.
Results
Protease inhibitors effectively inhibit cell-to-cell transfer
of HIV-1
To investigate the effect of PIs on cell-to-cell spread of
HIV-1 we used a well-established T cell co-culture system,
the validation of which is extensively described elsewhere
[31-34]. HIV-1 infected Jurkat T cells were either un-
treated or pre-incubated with the PI Lopinavair (LPV) or
Darunavir (DRV), incubated with uninfected target T cells
(Jurkat-1G5) and cell-to-cell spread of HIV-1 was mea-
sured by quantitative real-time PCR (qPCR) to enumerate
the appearance of de novo HIV-1 DNA pol copies that
arise from reverse transcription within the newly infected
T cell population. It has previously been confirmed that
using a synchronous population of HIV-1 infected cells
(>90% of Gag positive by flow cytometry) this assay reli-
ably measures virus infection of target cells mediated by
cell-to-cell spread with little or no contribution from cell-
free virus transfer that is significantly less efficient [32,33].
Treated and untreated infected cells used in our assay had
comparable Gag positivity after staining and analysis by
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treated and untreated donor cells respectively. Figure 1
shows that (as expected) we observe a time-dependent in-
crease in the appearance of HIV-1 pol DNA indicative of
cell-cell spread within the control sample that was incu-
bated in the absence of PI (Figure 1A and B). Notably,Figure 1 Protease Inhibitors effectively block cell-to-cell spread of HIV-
of Cmax LPV (14 μM) and B) Cmax of DRV (12 μM). HIV-1infected Jurkat cells (do
(targets) with or without PIs. After DNA extraction, qPCR performed to measu
gene and expressed as the fold-increase in HIV DNA copy number over time
error bars represent the standard deviation of the mean (SD), **** P < 0.0001, *
C) Reduced detection of 2-LTR circles following cell-to-cell spread of HIV-1 in th
cells with or without LPV, 2-LTR circles were detected by qPCR. ** P < 0.05, Unp
HIV-1+ donor cells incubated with PIs, RTIs or left untreated for 24 h. Virus-cont
lyzed by SDS-PAGE and western blotting for HIV-1 Gag. E) LPV and F) DRV sim
bated with serial dilutions of PI for 24 h, mixed with target cells and HIV-1 DNA
supernatant harvested from infected donor cells incubated with PI for 24 h wa
pelleted target cells and qPCR performed. Error bars represent the SD of the m
the efficacy of LPV in blocking cell-to-cell spread of HIV-1. ****P < 0.0001, ***P <cell-to-cell spread of HIV-1 was potently blocked in the
presence of both Lopinavir and Darunavir at doses corre-
sponding to the maximum plasma concentrations (Cmax)
(14 μM LPV; 12 μM DRV) achieved in vivo [35-37], with
no increase in HIV-1 DNA detected during co-culture in
the presence of drug (Figure 1A and B). Inhibiting de novo1. A) Quantification of cell-to-cell spread of HIV-1 over time in presence
nors) incubated with PI for 24 h and mixed with uninfected Jurkat cells
re appearance of HIV pol DNA. Data normalized to albumin housekeeping
relative to the baseline value at t = 0 h. Data show mean of triplicates,
**P<0.001, ns: not significant, two-way ANOVA plus Bonferroni post-test.
e presence of LPV (14 μM). After 24 h co-culture of donor cells and target
aired Student T-test. D) Confirmation of PI Gag maturation defect in HIV-1.
aining supernatants harvested, purified and equal volumes of virus ana-
ilarly inhibit cell-to-cell and cell-free HIV-1 spread. HIV-1 infected cells incu-
measured as described for A. For cell-free infections, virus-containing
s used to infect target cells. 24 h post-infection, DNA was extracted from
ean of triplicates G) Increasing donor: target cell ratio in co-culture reduces
0.001, ns: not significant, Two-way ANOVA with Bonferroni post-test.
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spread would also be expected to impact on the appear-
ance of 2-LTR circles that are used as a marker of HIV-1
nuclear import a step that immediately precedes proviral
integration [38]. We found that while 2-LTR circles were
readily detected (an average of 635 copies/100 ng of DNA
at 24 h) in co-cultures performed in the absence of PI, sig-
nificantly fewer 2-LTR circles were detected for co-cultures
performed in the presence of 14 μM LPV (<50 copies/100
ng of DNA) (Figure 1C). Taken together these data suggest
that PI can effectively inhibit HIV-1 cell-to-cell spread. To
confirm the appropriate activity of PIs on Gag maturation
and to ensure there was no defect in overall Gag budding,
we performed western blot analysis of purified virus col-
lected from PI treated HIV-1 infected T cells. Donor cells
treated with PIs (Cmax of LPV and DRV) showed the ex-
pected predominance of uncleaved p55Gag protein in vi-
rions whereas untreated cells or cells treated with RTIs
(Cmax TDF and NVP) contain predominantly p24CA indi-
cative of appropriate protease-mediated Gag cleavage
(Figure 1D).
Protease inhibitors are equally effective at blocking
cell-free and cell-to-cell spread of HIV-1
To determine the efficacy of PIs over a range of concen-
trations, and to compare inhibition of cell-free and cell-to-
cell spread, HIV-1 infected donor cells were co-cultured
with target cells in the presence of serial dilutions of LPV
and DRV and cell-to-cell spread was quantified by qPCR
to calculate the concentration at which 50% infection was
inhibited (IC50). To measure cell-free infection, the HIV-
1+ donor cells were incubated alone and allowed to pro-
duce virus in the presence of a dose titration of the PIs.
Culture supernatants containing cell-free virus were sub-
sequently harvested, used to infect target cells and infec-
tion was quantified by qPCR as described above. Infection
curves were generated to determine the IC50 for PIs in
both cell-to-cell and cell-free spread (Figure 1E and F and
Table 1). Notably, no significant difference was observed
in the IC50 of LPV and DRV for either cell-free (3.0 nM




Cell-cell Cell free Cell-cell Cell-free Cell-c
Mean IC50 2.9 nM 3.0 nM 2.8 nM 2.5 nM 359.8
SEM 0.2 0.2 0.4 0.1 89.
p-value 0.7 0.5
SEM = Standard error of the mean calculated from three independent experiments.
to estimate IC50s based on the sigmoidal dose response curves generated with Gra
IC50 values obtained for cell-to-cell vs. cell-free for LPV, DRV and NVP. The p-values
dose of drug tested.and 2.8 nM respectively) indicating that PIs are equally ef-
fective at inhibiting both modes of HIV-1 spread.
The reduced efficacy of antiretroviral therapy and neu-
tralizing antibodies during cell-to-cell spread has previ-
ously been attributed to the higher multiplicity of virus
transfer [15,16,39-42]. Therefore we assessed the effect
of varying the multiplicity of infection (MOI) on inhibition
of cell-to-cell spread by PIs by increasing the number of
donor cells in co-culture to achieve a donor-to-target ratio
of 5:1, compared to the 1:5 ratio that was used in our pre-
vious experiments. Figure 1G shows that increasing the
number of HIV-1 infected cells led to a reduced ability of
LPV to inhibit cell-to-cell infection when used at a con-
centration (8 nM) close to the IC50 (Table 1). Increasing
the concentration of LPV three-fold (24 nM) restored the
ability of LPV to block cell-to-cell spread at the higher
donor-to-target ratio (Figure 1G).
A protease inhibitor drug resistant variant maintains its
resistant phenotype in a cell-to-cell assay system
Next we investigated cell-to-cell spread of a PI drug re-
sistant variant of HIV-1 bearing resistance mutations to
LPV and compared this to wild-type virus. This variant has
a major drug resistance mutation in Protease (V82A) and a
compensatory p7/p1 cleavage site mutation (A431V) in
Gag, confers resistance to LPV and is the predominant mu-
tation selected for in vivo in patients receiving LPV [43,44].
The PI susceptibility of the mutant virus (termed HIV-1DM)
was confirmed in a cell-free drug resistance phenotyping
assay [45] and was found to be 11-fold more resistant
to LPV than the wild-type virus (HIV-1WT) (Figure 2A).
As expected both viruses were equally susceptible to
DRV (Figure 2B). To compare cell-to-cell spread of HIV-
1WT and HIV-1DM in the presence of PI, each virus was
incubated in the presence of serial dilutions LPV and cell-
to-cell spread was quantified by qPCR and IC50s cal-
culated. The drug resistant virus retained its resistance
phenotype in a cell-to-cell assay being approximately 7-
fold more resistant to LPV than the wild-type virus (IC50
5.6 nM and 37 nM respectively) (Figure 2C). Moreover,
the ability of the HIV-1DM to be better transmitted byvirus transfer with protease inhibitors and reverse
Reverse transcriptase inhibitors
Nevirapine Tenofovir Zidovudine
ell Cell -free Cell-cell Cell-free Cell-cell Cell-free
nM 86 nM >80 μM* 7.5 μM >80 μM 3.4 μM
5 9.2 UD 0.7 UD 0.3
0.03 UD UD
Because TDF and AZT do not titrate fully for cell-to-cell spread we were unable
phPad Prism software. A two-tailed student t-test was applied to compare the
obtained are shown in the table. UD = cannot be determined. * = Maximum
Figure 2 A PI resistant variant maintains its resistant phenotype during cell-to-cell spread. HIV-1DM displays enhanced resistance to A) LPV but
not B) DRV when compared to wild-type HIV-1. Cell-free virus was produced from 293T cells in the presence of serially diluted PI, used to infect HeLa
TZM-bl cells and infectivity was determined by luciferase assay. Data shown is a representative of two independent experiments. Error bars represent the
SD from the mean of duplicates. C) HIV-1DM maintains its resistant phenotype in a cell-to-cell spread assay system. Cell-to-cell spread of both resistant
and wild-type variants were quantified by qPCR as described in Figure 1 in the presence of a serial dilution of LPV. The dose-infection curves for each
virus were fitted with GraphPad Prism software. The data shown are a representative from three independent experiments. The error bars represent the
SD of the mean of triplicates.
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pared to wild-type virus) confirms that the inhibition we
see in the presence of PI is directly related to the anti-viral
drug activity.PI can block cell-to-cell spread mediated by HIV-1-infected
primary T cells
To determine if PIs were also able to block cell-to-cell
spread by HIV-1 infected primary cells, PBMCs were ob-
tained from healthy donors and CD4+ T cells were purified,
stimulated with PHA and IL2 and infected with HIV-1.
After 72 h these cells were treated with LPV and co-
cultured with uninfected target cells and cell-to-cell spread
was quantified by qPCR exactly as described in Figure 1.
Cell-to-cell spread of HIV-1 mediated by primary CD4+ T
cells was blocked by LPV at a dose corresponding to the
Cmax (14 μM) (Figure 3). Because we were unable to
achieve >90% infection of primary T cells (60% HIV-1 Gag
positive by flow cytometry) an additional control was in-
cluded in which HIV-1 infected T cells were cultured alone
without the addition of fresh uninfected target cells. These
data show no increase in HIV-1 pol DNA over time indicat-
ing that there is no ongoing spreading infection within the
primary cell population.Reverse transcriptase inhibitors are less effective inhibitors
of cell-to-cell spread compared to cell-free infection
In light of our results suggesting that PIs are similarly ef-
fective at inhibiting cell-to-cell and cell-free spread of
HIV-1, we next sought to evaluate the relative efficacy of
RTIs in our assay system since conflicting reports exist
regarding their ability to block cell-to-cell spread [20,23].
Serial dilutions of Nevirapine (NVP), Tenofovir (TDF)
and Zidovudine (AZT) were used in co-culture and cell-
free infection assays as described above and the average
IC50 values were calculated (Figure 4 and Table 1). Up to
four-fold higher concentrations of NVP (p < 0.03) and
greater than twenty-fold higher concentrations of TDF
were required to achieve a 50% inhibition of cell-to-cell
spread compared to cell-free infection (Figure 4A-C and
Table 1). Of note, TDF was unable to completely block cell-
cell spread even when used at a concentration greater than
twenty-fold the IC50 for cell-free transmission. This is in
contrast to the data we obtained with PIs, for which a simi-
lar concentration of the drugs was sufficient to inhibit both
cell-to-cell and cell-free spread (Figure 1D,E and Table 1).
Reducing the input of virus-infected cells ten-fold (by de-
creasing the number of donor cells used in co-culture to
achieve a donor-to-target ratio of 1:50) led to an increased
ability of TDF to inhibit cell-cell spread (Figure 4D).
Figure 3 Protease Inhibitors effectively block cell-to-cell transfer
from HIV-1 infected primary T cells: HIV-1 infected primary CD4+ T
cells (donor cells) were incubated with LPV (14 μM) for 24 h and
mixed with uninfected Jurkat cells (targets) and cell-to-cell spread
was quantified by qPCR as described in Figure 1. A representative
of two independent experiments performed with two different donors
is shown. Data are the mean and error bar represent the SD, **** P <
0.0001, *** P < 0.001, two-way ANOVA with Bonferroni post test.
Figure 4 Reverse transcriptase Inhibitors are less effective inhibitors o
Uninfected target cells were incubated with serial dilutions of A) Nevirapin
with an equal number of HIV-1 infected donor cells. At 24 h post-mixing, t
described in Figure 1. For cell-free infection, virus-containing supernatant h
the presence of a serial dilution of the relevant RTI. At 24 h post-infection,
The dose–response curves for both cell-free and cell-to-cell modes of sprea
representative of three independent experiments. Error bars represent the
ability of TDF to inhibit cell-to-cell spread. Co-cultures using ten-fold fewer
(IC50) and low dose concentration of TDF. Data show the means of triplica
*** P < 0.001, ns: not significant, Two-way ANOVA with Bonferroni post-test
Titanji et al. Retrovirology 2013, 10:161 Page 6 of 11
http://www.retrovirology.com/content/10/1/161Time of drug addition does not modify the effects of PIs
and RTIs on HIV-1 cell-to-cell spread
We also assessed the effects of time of drug addition on
the ability of PIs and RTIs to inhibit cell-to-cell HIV-1
transfer. For PIs, HIV-1 infected donor cells were
mixed with uninfected target cells in the presence of LPV
(Figure 5A) or DRV (Figure 5C) without prior pre-incu
bation of donors with the drug (time of addition, t = 0 h).
Notably PIs remained effective at inhibiting cell-to-cell
virus spread whether drugs were added at t = 0 h (Figure 5)
or when HIV-1 infected cells were pre-incubated with drug
for 24 h (Figure 1). A similar experiment was performed
using RTIs, in which uninfected target cells were pre-
incubated with TDF (Figure 5B) or AZT (Figure 5D) for 24
h prior to mixing with HIV-1 infected donor cells and cell-
to-cell spread quantified by qPCR. Under these conditions
it was found that pre-incubating target cells with the RTIs
for 24 h did not improve the ability of TDF and AZT to in-
hibit HIV-1 cell-to-cell spread. Taken together these data
show that time of drug addition does not modify the ef-
fects of PIs and RTIs on HIV-1 cell-to-cell spread.
Discussion
Here we have investigated whether PIs are able inhibit
cell-to-cell spread of HIV-1. The results presented hereinf HIV-1 cell-to-cell spread compared to cell-free infection.
e (NVP), B) Zidovudine (AZT) or C) Tenofovir (TDF) for 1 h and mixed
he DNA was extracted and cell-cell spread was measured by qPCR as
arvested from infected donor cells was used to infect target cells in
the target cells were pelleted, DNA extracted and qPCR was performed.
d were plotted for each drug and curves fitted. Data shown are a
SD of the mean of triplicates. D) Reducing the virus MOI restores the
donor cells were performed in the presence of a high, intermediate
tes and error bars represent the SD of the mean, **** P<0.0001,
.
Figure 5 Time of drug addition does not modify the effects of PIs and RTIs on HIV-1 cell-to-cell spread: HIV-1 infected Jurkat cells (donors)
were mixed target cells in the presence of A) of LPV (14 μM) and C) DRV (12 μM) without prior pre-incubation of donor cells with drugs (time
of addition t = 0 h). DNA was extracted at various times post-mixing and qPCR was performed as described in Figure 1. Data show mean of triplicates
and error bars represent the standard deviation of the mean (SD). For RTIs, uninfected Jurkat cells (targets) were pre-incubated with B) TDF (20 μM) or
D) AZT (10 μM) for 24 h prior to mixing with infected donor cells. DNA was extracted at various times post-mixing and qPCR was performed. Data show
mean of triplicates and error bars represent SD. *** P < 0.001, **** P < 0.0001, ns: not significant, two-way ANOVA with Bonferroni post-test.
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antiretroviral drugs in blocking T cell-to-T cell spread of
the virus. By contrast we find that the nucleoside/tide RT
inhibitors, Nevirapine, Zidovudine and Tenofovir display
reduced efficacy in a cell-to-cell spread model. In particu-
lar we note that for Tenofovir, doses up to twenty-fold
higher than the maximum plasma concentration (Cmax)
achieved in vivo did not inhibit cell-to-cell spread more
than 50%. These findings may have implications for the ef-
ficacy of therapeutic regimens containing NRTIs in con-
tributing to future functional cure approaches, and also
within pre-exposure prophylaxis approaches [46-48].
The fact that PIs maintain potency during cell-to-cell
spread, whereas RTIs lose activity is likely related to the
window of time during which these drugs have to act,
their biological function and the multiplicity of infection.
PIs prevent cleavage of viral polyproteins into functional
sub-units leading to the formation of immature non-
infectious virus particles. Exposure of HIV-1 infected
cells to a PI would generate a pool of virions unable to
mature and result in the transfer of non-infectious virus
across the virological synapse. Thus, the production of
non-infectious virus would have similar consequences
for HIV-1 dissemination by both cell-free and cell-to-cell
spread and indeed we find both modes of HIV-1 transmis-
sion are inhibited by PIs with similar IC50 values. Cell-to-
cell spread of HIV-1 is associated with high multiplicity of
infection that is achieved by a combination of polarizedvirus budding, clustering of virus entry receptors and the
close physical contact between cells limiting the require-
ment for prolonged virus [8,17,33,49,50]. Therefore, RTIs
that act within the target T cell may be more easily satu-
rated by the large amount of incoming infectious virions
transmitted at virological synapses. In support of this, we
found that cell-to-cell spread of HIV-1 was considerably
more resistant to RTIs than cell-free infection, in agree-
ment with previous reports [20,42]. The importance of the
MOI in this context was further evidenced by showing
that altering the relative ratio of infected and uninfected
cells impacted on the degree to which PIs and RTIs could
inhibit cell-to-cell spread. Interestingly, a recent study
suggests that PIs affect multiple distinct steps in the life-
cycle of the virus (down-stream of the well-defined block
to Gag maturation) including both viral entry and post-
entry events [30]. Therefore it is possible that the multiple
effects of PIs could also contribute to the particular effect-
iveness of this drug class at blocking cell-to-cell infection
by contrast to RTIs, which affect a well defined single-step
in viral replication.
Our results showing that RTIs have sub optimal efficacy
in cell-to-cell spread is similar to the observations of Sigal
et al. [20], who also found that TDF and Efavirenz (EFV)
were poor inhibitors of HIV-1 cell-to-cell spread when
compared to cell-free virus infection. However, in their
assay they found even larger differences between the con-
centrations of RTI that was required to inhibit cell-to-cell
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for the difference in IC50 is unclear but may be influenced
by their use of reporter gene and antigen transfer based
infection read-outs (which might overestimate the degree
of productive infection in target cells following co-culture
in the presence of inhibitors) whereas here we have mea-
sured viral DNA as a direct readout of infection. By con-
trast, Permanyer et al. [23] found RTIs to be equally
effective against both cell-free and cell-to-cell virus trans-
fer. However, that study did not directly compare the IC50
of the inhibitors for both modes of viral infection across a
clinically relevant range of drug concentrations as we have
done, and this may explain why their assays did not detect
the differences in the dose of RTIs required to block cell-
to-cell compared to cell-free infection. Another possible
source of variation could be that in the study by Per-
manyer et al., the virus input was adjusted so that cell-free
and cell-to-cell spread resulted in a similar percentage
of GFP+ infected cells in the untreated condition. Under
those conditions, the IC50 of AZT and TDF were found
to be equal. However, normalizing the virus input in this
way removes the quantitative effects of high-multiplicity
infection mediated by cell-cell spread. Here we have used
a direct method to measure cell-to-cell virus transfer by
detecting de novo HIV-1 DNA transcripts by qPCR and
have not adjusted virus input to achieve the same levels of
infection of target cells, therefore the quantitative effects
of cell-to-cell spread will remain. Taking this approach, we
find that RTIs are less effective than PIs at blocking cell-
cell spread. PI treatment resulted in inhibition of viral
DNA synthesis (reverse transcripts), and we infer from
these data that the inhibitory effect of PIs on cell-to-cell
infection occurs at or before reverse transcription, as ex-
pected. To confirm that inhibition of productive infection
through cell-to-cell spread by PIs was complete, we also
indirectly measured nuclear entry in the presence of PIs
by detection of 2-LTR circles in co-cultured cells. Follow-
ing 24 h of co-culture in the presence of PIs, virtually no
2-LTR circles were detected compared to the no drug con-
trol. Although 2-LTR circles are non-functional forms of
intracellular HIV-1 DNA they can serve as surrogate
markers of nuclear import of viral DNA as well as for the
completion of reverse transcription [38]. We were also able
to confirm this effect of PIs on cell-to-cell spread of HIV-1
mediated by HIV-1 infected primary CD4+ T cells.
Here we have used a well-validated laboratory isolate
of HIV-1 to evaluate the relative efficacy of PI during
cell-cell spread of HIV-1. Currently there is no compel-
ling evidence that HIV-1 subtypes need to be considered
in the choice of first or second line cART; however it would
be informative in future work to expand these studies and
include a panel of different HIV1- strains and clinical iso-
lates, to evaluate other drug classes such as integrase inhibi-
tors and consider the effectiveness of combination therapyduring cell-free and cell-cell spread. Furthermore, while PI
based intensification studies to date have not shown any
reduction in the viral load of patients, these studies have
measured plasma viremia [51,52]. Therefore it will be
interesting to revisit this idea in clinical studies by directly
measuring viral replication in lymphoid tissues - sites where
cell-to-cell spread likely predominates and where compart-
mentalized viral replication may be supported. Under these
conditions, one may speculate that PI-containing cART
regimens may be more likely to have an impact on viral
reservoirs.Conclusions
In conclusion we show that PIs are equally effective against
both modes of HIV-1 spread between T lymphocytes and
are more effective than RTIs in blocking equivalent cell-
associated viral dissemination in vitro. Our data with RTIs
support the previous suggestion that the variable effects of
antiviral drugs on cell-to-cell spread of HIV-1 may impact
ongoing viral replication, with the caveat that this would
be dependent on both the drug-class and the multiplicity
of infection (i.e. the number of infected cells relative to the
in vivo drug concentration). Whether the high multiplicity
of infection required to overcome RTIs occurs in vivo is
difficult to evaluate. However, saturation of antiviral drugs
by cell-to-cell spread may be more feasible in sanctuary
sites such as lymphoid tissues, where cell-to-cell spread
predominates and in which diffusion of antiviral agents
may be reduced [1]. Therefore the variable effects of ART
on cell-to-cell spread may need to be considered in future
therapeutic strategies.Methods
Cells, viruses and inhibitors
HeLa-TZMbl cells were obtained from the Center for
AIDS Reagents, National Institutes of Biological Standard
and Control, UK (CFAR, NIBSC) and donated by J. Kappes,
X. Wu and Tranzyme Inc. HEK 293T cells were originally
from the ATCC (American Type Culture Collection). Ad-
herent cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal calf serum
(FCS, Invitrogen), 50 U of penicillin/ml and 50 μg/ml of
streptomycin. The CD4+/CXCR4+ T cell line Jurkat CE6.1
and derivative Jurkat line 1G5 (obtained through AIDS Re-
search and Reference Reagent Program, Division of AIDS,
NIAID, NIH [ARRP]: from Dr. Estuardo Aguilar-Cordova
and Dr. John Belmont) were maintained in RPMI 1640 sup-
plemented with 10% FCS and 50 U/ml of penicillin and 50
μg/ml of streptomycin. The HIV-1 clone pNL4.3 was pro-
duced by Dr. Malcolm Martin and obtained from the
ARRP. The HIV-1 PIs Lopinavir (LPV) and Darunavir
(DRV) and the RTIs Nevirapine (NVP), Zidovudine (AZT)
and Tenofovir (TDF) were obtained from the ARRP.
Titanji et al. Retrovirology 2013, 10:161 Page 9 of 11
http://www.retrovirology.com/content/10/1/161Quantitative real-time PCR assay for cell-to-cell spread
and inhibitor assays
Jurkat cells were infected by spinoculating at 1200× g for
2 h at an MOI of 0.1-0.3. HIV infected cells were used
48–72 hours post-spinoculation when >90% of the cells
were infected. To measure cell-to-cell transfer a quanti-
tative real-time PCR (qPCR) [32,33] with minor modifi-
cations. Briefly, HIV-1 infected cells were washed and
2×105 cells per well were pre-incubated with protease in-
hibitors LPV or DRV for 24 h at 37°C. 8×105 uninfected
Jurkat 1G5 target cells were subsequently added and co-
cultures were supplemented with fresh drug and incu-
bated for 0 h, 1 h, 3 h, 6 h, 12 h or 24 h at 37°C after
which the cells were pelleted, stored at −80°C and gen-
omic DNA was extracted (QIAGEN). Quantitative real-
time PCR was performed to measure cell-to-cell spread as
described previously using primers and probes specific for
HIV-1 pol DNA and the housekeeping gene albumin
[32,33]. For experiments to calculate the IC50 of inhibi-
tors, co-cultures were performed in the presence of a ser-
ial dilution of the inhibitor under study and incubated for
24 h before DNA extraction and qPCR. For cell-free infec-
tion experiments, virus produced from 2×105 donor cells
pre-incubated with drug for 24 h was used to infect 1×106
target cells by spinoculating at 1200 g for 2 h. After 24 h
incubation, the cells were pelleted, supernatant aspirated
and frozen for DNA extraction and subsequently analyzed
by qPCR. For RTIs, experiments were performed exactly
as described above, except that uninfected target cells
were incubated with Nevirapine (NVP), Zidovudine
(AZT) or Tenofovir (TDF) for 1h at 37°C prior to the
addition of HIV-1 infected donor cells. Fifty percent in-
hibitory concentrations (IC50s) were determined using
Prism GraphPad Software.
For primary cell experiments, peripheral blood mono-
nuclear cells (PBMC) were isolated from buffy coats (from
the National Blood Transfusion Service, London, United
Kingdom) by Ficoll-Hypaque (Sigma-Aldrich) gradient cen-
trifugation. CD4+ T cells were isolated by negative selection
according to manufacturer’s instructions (Miltenyi Biotec)
and were routinely >90% pure. Primary CD4+ T cells were
activated with RPMI supplemented with 1 μg/ml of PHA-L
(Sigma) and 10 IU/ml of interleukin-2 (IL-2; NIBSC) for 3
days. CD4+ T cells were subsequently infected with HIV-1
at an MOI of 1 by spinoculating as described above. Three
days later the cells were stained for Gag and analyzed by
FACS to determine the % infection. HIV-1 infected primary
CD4+ T cells were treated with LPV (Cmax 14 μM), co-
cultured with uninfected Jurkat 1G5 cells (targets) and cell-
to-cell spread was quantified by qPCR as described above.
Real-time PCR for the detection of 2-LTR circles
To quantify 2-LTR circles in the presence or absence of
inhibitors, co-cultures of donor cells mixed with targetcells with or without inhibitors were performed as de-
scribed above. The cells were pelleted at 0 h and 24 h
and total DNA extracted. 2-LTR circles were quantified
in triplicate by qPCR as described by Apolonia et al.
[53]. The primers used were 5′-AACT AGAGATCCCT
CAGACCCTTTT-3′ and 5′-CTTGTCTTCGTTGGGA
GTGAATT-3′, and Taqman probe 5′-CTAGAGATTTT
CCACACTGAC-3′ [53]. To estimate the number of 2-
LTR circles in target cells at the 24 h time-point all the
values were normalized to the 0 h time-point which rep-
resents the number of 2-LTR circles in the donor cells at
the time of mixing donors with targets.
Flow cytometry
HIV-1 infected Jurkat cells were washed and fixed with
3% paraformaldehyde (PFA), permeabilized in BD™ Perm
Buffer (BD Biosciences) and stained with anti-HIV p24
monoclonal antibody conjugated to fluorescein isothio-
cyanate (HIV-1 p24 (24–4) FITC, Santa Cruz Biotechnol-
ogy) to detect intracellular Gag. Acquisition was performed
using a Becton Dickinson FACS Calibur and data analyzed
using FlowJo® software. Cells were used when >90% were
Gag positive.
Western blotting
Viral supernatants were harvested from HIV-1 infected
T cells and virions purified by sucrose gradient centrifu-
gation. Equal volumes of purified virus were separated
by SDS-PAGE and analyzed by Western blotting using
rabbit antisera raised against HIV-1 Gag that recognizes
p55Gag and p24CA (donated by Dr G. Reid and ob-
tained from the CFAR). Primary antibody was detected
with goat anti-rabbit HRP (DAKO) and visualized by
ECL (Amersham).
Construction of a protease inhibitor resistance virus
To construct the drug resistant variant of NL43, site-
directed mutagenesis was performed with Accuprime Pfx
supermix (Invitrogen®) using forward and reverse primers
containing the required nucleotide substitutions. Two mu-
tations, V82A (mutagenesis primers: forward-5′- GTAG
GACCTACACCTGCCAACATAATTGGAAG-3′, reverse-
5′-CAGATTTCTTCCAATTATGTTGGCAGGTGTAGG-
3′), a major protease drug resistance mutation and A431V
(mutagenesis primers: forward-5′-GAAAGATTGTACT
GAGAGAGACAGGTTAATTTTTTAGG-3′), a cleavage
site-mutation in the p7/p1 junction, were introduced to
make HIV-1DM (DM= double mutant). The mutagenesis
was carried out in the vector pCR® 2.1 TOPO, by sub-
cloning a region of HIV-1NL4.3 covering nucleotides 740–
2940. Sequencing was performed by BigDye terminator
chemistry and a 3730xl analyzer (ABI®) to confirm the
presence of the mutations introduced and the absence
of any other substitutions. The mutated fragment was
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digestion. Stocks of infectious virus (HIV-1DM and HIV-
1WT) were made by transfecting 293T cells using Fugene 6
(Promega). Infectious viral titers were measured on HeLa-
TZMbl reporter cells using the Bright-Glo Luciferase assay
kit (Promega).Drug susceptibility assay
An in-house assay was used to determine the drug suscep-
tibility of the mutant virus compared to the wild-type vec-
tor [45]. The assay was modified to accommodate the use
of plasmids with full-length HIV-1 genomes. HEK 293T
cells were transfected as described above, 16 h later the
cells were seeded in the presence of a serial dilution of PIs.
Virus supernatant was harvested 24 h later and used to in-
fect fresh target HeLa-TZMbl cells by spinoculating for 2 h
at 1200× g. Replication was determined by measuring lucif-
erase expression in infected target cells at 48 h post-
infection using SteadyGlo luciferase assay system® (Pro-
mega) and expressed relative to that of no drug controls.
Fifty percent inhibitory concentrations (IC50s) were deter-
mined using Prism GraphPad Software. The IC50 values
calculated are the mean of at least two independent
experiments.Statistical analysis
A two-tailed student t-test was performed to compare
the mean IC50s for cell-free and cell-to-cell spread for
PIs and RTIs. For comparisons of data with more than
two groups a two-way ANOVA with Bonferroni post-test
for multiple comparisons was used.Ethical approval
Experiments performed with blood from human volun-
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